Literature DB >> 8818606

Pattern of pS2 protein expression in premalignant and malignant lesions of gastric mucosa.

J C Machado1, F Carneiro, N Blin, M Sobrinho-Simões.   

Abstract

The aim of this study was to evaluate the pattern of pS2 protein expression in premalignant and malignant lesions of gastric epithelium. We analysed, by immunohistochemistry, the pS2 expression in six samples of normal gastric mucosa, 18 cases of chronic atrophic gastritis with intestinal metaplasia (IM), 10 hyperplastic polyps, 11 adenomatous polyps and 50 gastric carcinomas, together with the respective samples of adjacent non-neoplastic mucosa. pS2 is expressed throughout foveolar and superficial epithelium of normal gastric mucosa and this pattern is retained in chronic atrophic gastritis out of IM lesions. pS2 expression is confined to goblet cells in complete IM and occurs both in goblet and columnar cells in incomplete IM. Hyperplastic polyps displayed significantly higher pS2 expression than adenomatous polyps. In gastric carcinomas, pS2 expression was observed in 66.0% of cases, being significantly higher in diffuse (88.9%) than intestinal type carcinomas (53.6%). A subset of carcinomas of the latter group displayed pS2 immunoreactivity in a high percentage of cells with a pattern similar to that of hyperplastic polyps. Our results demonstrate there are major changes in pS2 expression, which can be used as a marker of gastric-type differentiation during the process of gastric carcinogenesis, and support the existence of at least two pathways of malignant transformation of gastric mucosa: one via intestinal metaplasia and adenomatous dysplasia, leading to glandular carcinomas with intestinal-type differentiation, the other via hyperplastic changes or de novo changes, leading to diffuse carcinomas and to a subset of glandular carcinomas displaying gastric-type differentiation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8818606     DOI: 10.1097/00008469-199606000-00005

Source DB:  PubMed          Journal:  Eur J Cancer Prev        ISSN: 0959-8278            Impact factor:   2.497


  6 in total

Review 1.  Trefoil peptides.

Authors:  W M Wong; R Poulsom; N A Wright
Journal:  Gut       Date:  1999-06       Impact factor: 23.059

2.  Epithelial dysplasia of the stomach with gastric immunophenotype shows features of biological aggressiveness.

Authors:  Pedro Valente; Mónica Garrido; Irene Gullo; Helena Baldaia; Margarida Marques; Francisco Baldaque-Silva; Joanne Lopes; Fátima Carneiro
Journal:  Gastric Cancer       Date:  2014-08-22       Impact factor: 7.370

Review 3.  GATA factors in gastrointestinal malignancy.

Authors:  Funmi Ayanbule; Narasimhaswamy S Belaguli; David H Berger
Journal:  World J Surg       Date:  2011-08       Impact factor: 3.352

4.  Tests for serum levels of trefoil factor family proteins can improve gastric cancer screening.

Authors:  Susumu Aikou; Yasukazu Ohmoto; Toshiaki Gunji; Nobuyuki Matsuhashi; Hiroshi Ohtsu; Hirona Miura; Kensuke Kubota; Yukinori Yamagata; Yasuyuki Seto; Atsushi Nakajima; James R Goldenring; Michio Kaminishi; Sachiyo Nomura
Journal:  Gastroenterology       Date:  2011-05-27       Impact factor: 22.682

5.  Loss of pS2 protein expression is an early event of intestinal-type gastric cancer.

Authors:  M S Wu; C T Shun; H P Wang; W J Lee; T H Wang; J T Lin
Journal:  Jpn J Cancer Res       Date:  1998-03

6.  C/EBPβ regulates homeostatic and oncogenic gastric cell proliferation.

Authors:  Goncalo Regalo; Susann Förster; Carlos Resende; Bianca Bauer; Barbara Fleige; Wolfgang Kemmner; Peter M Schlag; Thomas F Meyer; José C Machado; Achim Leutz
Journal:  J Mol Med (Berl)       Date:  2016-08-13       Impact factor: 4.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.